Teyenkang Subsidiary Receives Drug Registration Certificate for Diquafosol Sodium Eye Drops

财中社··CNJP·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Teyenkang's wholly owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. has received the Drug Registration Certificate for Diquafosol Sodium Eye Drops issued by the National Medical Products Administration. The eye drops are indicated for dry eye patients diagnosed with keratoconjunctival epithelial damage accompanied by tear abnormalities. The original drug was developed by Santen Pharmaceutical Co., Ltd. According to data from the Moxiang Pharmaceutical Drug Sales Database, total terminal sales of Diquafosol Sodium Eye Drops in 2023 amounted to 228 million yuan. In the first half of 2026, Teyenkang achieved revenue of 320 million yuan and net profit attributable to the parent company of 3.72 million yuan.

Impact on assets 2

Health Care▲
Santen Pharmaceutical Co., Ltd.
4536
± MixedCompetitionrelevance

Named only as the developer of the original Diquafosol Sodium Eye Drops, implying a new generic competitor but with no stated impact.

Others▲

Off-coverage companies 1

山东华铂凯盛生物科技有限公司i
Private▲ PositiveRegulationrelevance

The subsidiary itself received the NMPA Drug Registration Certificate for Diquafosol Sodium Eye Drops.